All articles tagged with #depression
Psychotherapist Niro Feliciano has adopted a new diagnostic approach, asking new clients about their screen time habits before assessing other symptoms of depression. This shift reflects growing evidence that excessive device use can mimic or exacerbate depressive symptoms through dopamine dysregulation.
Two new studies suggest that mental health interventions may improve cancer outcomes. A PLOS Medicine analysis found that patients on SSRIs had a 37% lower death risk during immunotherapy, while a SEER-Medicare study linked early psychotherapy to a 21% reduction in cancer-specific mortality. Both findings are observational and require further trials to confirm causality.
A 34-year Australian study finds that higher cardiorespiratory fitness in childhood is associated with a 15-20% lower risk of depression in adulthood, with stronger effects observed in women.
Recent medical discussions highlight that brain fog is not a single condition but a symptom with diverse biological origins. While hormonal shifts during menopause are a primary driver for midlife women, other factors include neuroinflammation, cellular energy failure, and residual effects from depression. Experts emphasize that subjective cognitive decline often precedes clinical detection, requiring personalized assessments rather than standard testing.
A University of Helsinki study using magnetoencephalography (MEG) identified five distinct neurophysiological subtypes of major depressive disorder. By analyzing functional brain connectivity in 263 patients, researchers found that individuals with the same clinical diagnosis can exhibit opposite brain activity patterns, ranging from hyper-connectivity linked to substance abuse to hypo-connectivity associated with PTSD. This suggests depression is biologically heterogeneous, potentially explaining conflicting prior research and paving the way for personalized treatment, though clinical application is not yet immediate.
A CDC/NCHS analysis finds about 71.5% of U.S. adults experienced fatigue on multiple days in the past three months, with higher rates among women and younger adults; fatigue correlates with depression, anxiety, and cognitive difficulties and is linked to activity limitations. Experts recommend the American Heart Association's Life's Essential 8 and active rest strategies to manage fatigue.
Xenon Pharmaceuticals paused enrollment in its phase 3 depression programs X-Nova2 (major depressive disorder) and X-Ceed (bipolar depression) after reports of adverse events including psychosis. Existing participants remain in treatment while the company plans to adjust dosing to improve tolerability and has notified the FDA. X-Nova2 enrollment was about 360 participants (roughly 80% of the target). Xenon says the MDD trial already has enough patients to show a meaningful improvement, with topline data expected in Q1 next year. Analysts view the safety signals as not indicative of a broader Kv7 activator safety issue, and the epilepsy program data remain supportive; Xenon’s stock traded lower following the announcement.
A critical review reevaluates the neurogenic hypothesis of depression in humans in light of new data on adult hippocampal neurogenesis, highlighting heterogeneous postmortem findings and recent advances in human-specific neurogenesis research. It emphasizes immature granule neurons as a potential, understudied element that may be affected by stress, inflammation, and antidepressant treatment, and discusses how human data are reshaping causal models, regional hippocampal differences, and therapeutic targets. The article also outlines research directions to clarify the role of immature neurons in depression and resilience and to explore their translational potential for treatment.
Michael Sweetney, Georgetown’s All-American forward and No. 9 pick in the 2003 NBA Draft, has died at 43. He starred for the Hoyas, played four NBA seasons with the Knicks and Bulls, continued his career overseas, and later coached at Yeshiva University. His family did not disclose a cause of death, and the article notes his public discussion of depression after his father’s 2003 passing.
A large Mendelian randomization study using genetic proxies for GLP-1 receptor activation links lifelong GLP-1 pathway activity to improved mental well-being and lower risks of major depressive disorder (OR 0.82 per 1 kg/m2 BMI reduction) and bipolar disorder (OR 0.61), with hints of protection against substance-use disorders. The benefits appear partly independent of weight loss, suggesting direct brain effects, but clinical trials are needed to confirm whether GLP-1 drugs yield the same psychiatric gains and to clarify underlying mechanisms.
Researchers analyze the Sina Weibo Depression Dataset to quantify how idealized sentiment toward urban places relates to depression risk across 88 place types. They build a place-sentiment index (LooM) and use an explainable deep-learning model, finding that depressed individuals express more emotionally mixed language, with surprisingly positive sentiment toward cultural and residential areas associated with higher depression risk. These signals show systemic, city-level patterns that scale with population and vary across Chinese cities, challenging the assumption that positive online sentiment equates to good mental health and highlighting the need for urban design to address residents’ subjective emotional needs.
Since the pandemic, anxiety and depression have risen and antidepressant prescriptions have surged, with about one in six American adults taking them and SSRIs making up the majority. The piece argues the trend is nuanced: some overuse is possible, but expanded access to mental health care—especially through primary care and telehealth—has also helped people in need. Prescribing is mainly done in primary care, and stopping antidepressants can be difficult for some, though gradual tapering under medical supervision is often possible. Systemic barriers mean many with serious depression still receive limited treatment, underscoring the need to balance medication with nonpharmacological options and broader access to care.
Hunter Hardin, a 30-year-old adult-content creator and burlesque performer known as LuLu LoveBottom, died by suicide on September 7, with friends confirming after a farewell Instagram post. A former high school football player, he publicly discussed depression and used his burlesque persona to express pain and identity. His friend Asura paid tribute, praising his ability to light up a room. Crisis resources are available at 988lifeline.org or by calling/texting 988 for those affected by his passing.
As GLP-1 weight-loss meds become more common, many patients experience weight regain after stopping due to cost or access, which can affect mood and engagement in care. Clinicians should start long-term nutrition, activity, and behavioral plans early, screen for depressive symptoms in primary care, use patient-centered language, normalize emotional responses to weight changes, and consider behavioral health referrals. Emphasize health metrics beyond the scale, employ shared decision-making, and set small, actionable steps with timely follow-up. If feasible, discuss restarting medication or implementing a time-limited behavioral plan to rebuild momentum while addressing barriers.
An observational study of 27,741 South Korean adults found that prescription weight‑loss medication users had higher rates of depression, mental-health counseling, suicidal thoughts and behaviors than non-users, with stronger associations among those who gained weight. The study cannot prove that the medications cause these mood changes, and older anti‑obesity drugs were analyzed. Experts call for baseline mental‑health screening and ongoing monitoring, and more research to separate drug effects from obesity‑related factors.